NCT03182751View on ClinicalTrials.gov

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Hip FracturesIntertrochanteric Fractures
Interventions
DRUG

Tranexamic Acid (TXA)

Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER